Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic indexRobert P. Lyon, Peter D. Senter, Patrick Burke et al.|Nature Biotechnology|2015Cited by 521
SGN-CD33A: a novel CD33-targeting antibody–drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AMLMay S.K. Sutherland, Julie A. McEarchern, Kerry Klussman et al.|Blood|2013Cited by 385
A Potent Anti-CD70 Antibody–Drug Conjugate Combining a Dimeric Pyrrolobenzodiazepine Drug with Site-Specific Conjugation TechnologyScott C. Jeffrey, Peter D. Senter, Nicole M. Okeley et al.|Bioconjugate Chemistry|2013Cited by 246
Development of orally active inhibitors of protein and cellular fucosylationNicole M. Okeley, Peter D. Senter, Kerry Klussman et al.|Proceedings of the National Academy of Sciences|2013Cited by 189